3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease
申请人:CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
公开号:US20150307492A1
公开(公告)日:2015-10-29
The present invention relates to a compound of formula (I′) or a pharmaceutically acceptable salt, solvate or hydrate thereof, in which: X
3
is F, OH or SH, Y
3
is F, OH or SH, X
1
, X
2
, X
4
, X
5
, Y
1
, Y
2
, Y
4
and Y
5
are, independently of one another, H, F, Cl, Br, OH or SH, and 1 to 2 groups among the X
1
, X
2
, X
4
and X
5
radicals are other than H and/or 1 to 2 groups among the Y
1
, Y
2
, Y
4
and Y
5
radicals are other than H. The present invention also relates to a compound of formula (I′) for use as a medicament, in particular in the prevention and/or treatment of cognitive disorders associated with a dysfunction of the Dyrk1A protein.
本发明涉及一种具有以下结构的化合物(I′)或其药学上可接受的盐、溶剂或水合物,其中:X3为F、OH或SH,Y3为F、OH或SH,X1、X2、X4、X5、Y1、Y2、Y4和Y5分别独立地为H、F、Cl、Br、OH或SH,且在X1、X2、X4和X5基团中的1到2个基团不是H,和/或在Y1、Y2、Y4和Y5基团中的1到2个基团不是H。本发明还涉及一种具有结构式(I′)的化合物,用作药物,特别是用于预防和/或治疗与Dyrk1A蛋白功能障碍相关的认知障碍。